Precigen, Inc.
PGEN Healthcare Biotechnology
Precigen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, up 146.7% from fiscal 2024. In the quarter to June 2026, revenue grew 6,322.7%, EPS grew 166.7% and free cash flow grew 8.73%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow PGEN
Precigen, Inc. (PGEN) EV/Sales
As of 16 October 2026, Precigen, Inc. (PGEN) trades at a EV/Sales of 27.2×. Over the past ten years it has ranged from −126× (April 2022) to 24,389× (July 2021); the current reading is higher than 58% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 136× | 140.57% |
| FY2024 | 56.5× | 16.58% |
| FY2023 | 48.5× | 427.47% |
| FY2022 | 9.2× | (83.70%) |
| FY2021 | 56.4× | 1.64% |
| FY2020 | 55.5× | 409.90% |
| FY2019 | 10.9× | 97.03% |
| FY2018 | 5.5× | (21.42%) |
| FY2017 | 7.0× | (49.63%) |
| FY2016 | 14.0× | (21.55%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 24.5× | (45.48%) |
| Mar 2026 | 45.0× | (66.91%) |
| Dec 2025 | 136× | (13.84%) |
| Sep 2025 | 158× | 79.77% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MBX MBX Biosciences, Inc. compare | n/m |
| DYN Dyne Therapeutics, Inc. compare | n/m |
| ELVN Enliven Therapeutics, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. compare | 2.4× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 4.7× |
| ADMA ADMA Biologics Inc compare | 4.9× |
| BEAM Beam Therapeutics Inc. compare | 8.9× |
| PGEN Precigen, Inc. | 27.2× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 254× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)